Summary of Clinical Use

In 2003 the FDA granted abagovomab orphan drug designation for the treatment of the epithelial ovarian cancer. Abagovomab is being assessed as a maintenance therapy for patients with advanced ovarian cancer, with the aim of prolonging the disease-free interval or preventing recurrence [6-7]. Phase 3 clinical trial NCT00418574 was terminated [2].

Mechanism Of Action and Pharmacodynamic Effects

Introducing the anti-idiotype antibody to patients induces an immune response to the mimicked antigen, with the desired result being immune system-directed destruction of tumour cells expressing CA-125 [2]. Sabbatini et al (2013) report that although repeated administration of abagovomab induces the desired immune response, this does not increase recurrence-free survival (RFS) or overall survival (OS) [4] in ovarian cancer patients in first remission .

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT00418574	Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients	Phase 2/Phase 3 Interventional	Menarini Group